The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...